Loss of Expression of the p16 Tumor Suppressor Gene Is More Frequent in Advanced Ovarian Cancers Lacking p53 Mutations
- 1 December 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 83 (3), 491-500
- https://doi.org/10.1006/gyno.2001.6464
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Alterations of the p16INK4A gene in human ovarian cancersMolecular Carcinogenesis, 1997
- Inactivation ofp16/CDKN2 andp15/MTS2 genes in different histological types and clinical stages of primary ovarian tumorsInternational Journal of Cancer, 1996
- 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancersNature Medicine, 1995
- Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.Proceedings of the National Academy of Sciences, 1994
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- The p53 tumor suppressor gene frequently is altered in gynecologic cancersAmerican Journal of Obstetrics and Gynecology, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- The p53 tumour suppressor geneNature, 1991
- The p53 proto-oncogene can act as a suppressor of transformationCell, 1989
- Reactivity of a monoclonal antibody with human ovarian carcinoma.Journal of Clinical Investigation, 1981